Iovance Biotherapeutics
Iovance Biotherapeutics is a clinical-stage biotechnology company dedicated to developing and commercializing innovative cancer immunotherapies that utilize the body's immune system to target and eliminate cancer cells. The company is primarily focused on tumor infiltrating lymphocytes (TIL) therapies, with lead product candidates including lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. Iovance is also exploring TIL therapies for various other cancers, such as squamous cell carcinoma of the head and neck and non-small cell lung cancer, through sponsored and collaborative clinical trials. The company has established partnerships with notable institutions, including Moffitt Cancer Center and the National Cancer Institute, to advance its research efforts. Founded in 2007 and headquartered in San Carlos, California, Iovance Biotherapeutics aims to be a leader in the development of personalized T-cell therapies for solid tumors, preparing for potential regulatory approvals and commercialization of its novel treatments.
Genesis Biopharma, Inc. Merge with Lion Biotechnologies, Inc. Genesis Biopharma, Inc. (OTCBB: GNBP) is developing autologous cell therapies for the treatment of cancer. Our lead product candidate, Cōntego™, is an autologous cell therapy using tumor infiltrating lymphocytes (TILs) indicated for the treatment of metastatic melanoma. Cōntego™ is being developed as a ready-to-infuse autologous cell therapy product. Following resection of the patient’s tumor, TILs are isolated from the resected tumor, and expanded in vitro to several billion cells. The expanded TILs are then infused into the patient where they attack the melanoma tumors regardless of their location in the body. Cōntego™ is based on the adoptive cell therapy regimen using tumor infiltrating lymphocytes invented by Dr. Steven A. Rosenberg, Chief, Surgery Branch, Center for Cancer Research, National Cancer Institute for the treatment of metastatic melanoma. Dr. Rosenberg’s adoptive cell therapy is presently available as a physician-sponsored investigational therapy for the treatment of Stage IV metastatic melanoma at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.